Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1989 1
1991 1
1992 1
1993 4
1994 3
1995 4
1996 5
1997 3
1998 5
2000 2
2003 1
2008 1
2009 2
2020 1
2021 2
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

36 results
Results by year
Filters applied: . Clear all
Page 1
Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants.
Ku Z, Xie X, Hinton PR, Liu X, Ye X, Muruato AE, Ng DC, Biswas S, Zou J, Liu Y, Pandya D, Menachery VD, Rahman S, Cao YA, Deng H, Xiong W, Carlin KB, Liu J, Su H, Haanes EJ, Keyt BA, Zhang N, Carroll SF, Shi PY, An Z. Ku Z, et al. Among authors: keyt ba. Nature. 2021 Jul;595(7869):718-723. doi: 10.1038/s41586-021-03673-2. Epub 2021 Jun 3. Nature. 2021. PMID: 34082438 Free PMC article.
Structure, Function, and Therapeutic Use of IgM Antibodies.
Keyt BA, Baliga R, Sinclair AM, Carroll SF, Peterson MS. Keyt BA, et al. Antibodies (Basel). 2020 Oct 13;9(4):53. doi: 10.3390/antib9040053. Antibodies (Basel). 2020. PMID: 33066119 Free PMC article. Review.
Multimeric Anti-DR5 IgM Agonist Antibody IGM-8444 Is a Potent Inducer of Cancer Cell Apoptosis and Synergizes with Chemotherapy and BCL-2 Inhibitor ABT-199.
Wang BT, Kothambawala T, Wang L, Matthew TJ, Calhoun SE, Saini AK, Kotturi MF, Hernandez G, Humke EW, Peterson MS, Sinclair AM, Keyt BA. Wang BT, et al. Among authors: keyt ba. Mol Cancer Ther. 2021 Dec;20(12):2483-2494. doi: 10.1158/1535-7163.MCT-20-1132. Epub 2021 Oct 28. Mol Cancer Ther. 2021. PMID: 34711645 Free article.
Antibody discovery via multiplexed single cell characterization.
Harriman WD, Collarini EJ, Sperinde GV, Strandh M, Fatholahi MM, Dutta A, Lee Y, Mettler SE, Keyt BA, Ellsworth SL, Kauvar LM. Harriman WD, et al. Among authors: keyt ba. J Immunol Methods. 2009 Feb 28;341(1-2):135-45. doi: 10.1016/j.jim.2008.11.009. Epub 2008 Dec 16. J Immunol Methods. 2009. PMID: 19087879 Free PMC article.
Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients.
Collarini EJ, Lee FE, Foord O, Park M, Sperinde G, Wu H, Harriman WD, Carroll SF, Ellsworth SL, Anderson LJ, Tripp RA, Walsh EE, Keyt BA, Kauvar LM. Collarini EJ, et al. Among authors: keyt ba. J Immunol. 2009 Nov 15;183(10):6338-45. doi: 10.4049/jimmunol.0901373. Epub 2009 Oct 19. J Immunol. 2009. PMID: 19841167 Free article.
A faster-acting and more potent form of tissue plasminogen activator.
Keyt BA, Paoni NF, Refino CJ, Berleau L, Nguyen H, Chow A, Lai J, Peña L, Pater C, Ogez J, et al. Keyt BA, et al. Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3670-4. doi: 10.1073/pnas.91.9.3670. Proc Natl Acad Sci U S A. 1994. PMID: 8170967 Free PMC article.
A fully human monoclonal antibody (CR002) identifies PDGF-D as a novel mediator of mesangioproliferative glomerulonephritis.
Ostendorf T, van Roeyen CR, Peterson JD, Kunter U, Eitner F, Hamad AJ, Chan G, Jia XC, Macaluso J, Gazit-Bornstein G, Keyt BA, Lichenstein HS, LaRochelle WJ, Floege J. Ostendorf T, et al. Among authors: keyt ba. J Am Soc Nephrol. 2003 Sep;14(9):2237-47. doi: 10.1097/01.asn.0000083393.00959.02. J Am Soc Nephrol. 2003. PMID: 12937299 Free article.
36 results